Eton Pharmaceuticals - ETON Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 176.07%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.26
▼ -0.08 (-2.40%)

This chart shows the closing price for ETON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eton Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ETON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ETON

Analyst Price Target is $9.00
▲ +176.07% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Eton Pharmaceuticals in the last 3 months. The average price target is $9.00, with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 176.07% upside from the last price of $3.26.

This chart shows the closing price for ETON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Eton Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2024Craig HallumInitiated CoverageBuy$8.00Low
12/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
8/11/2023HC WainwrightBoost TargetBuy ➝ Buy$9.00 ➝ $10.00Low
7/3/2023HC WainwrightLower Target$10.00 ➝ $9.00Low
3/21/2023HC WainwrightReiterated RatingBuy$10.00Low
9/26/2022HC WainwrightBoost TargetBuy$9.00 ➝ $10.00Low
8/12/2022HC WainwrightReiterated RatingBuy$9.00Low
7/25/2022HC WainwrightReiterated RatingBuy$11.00 ➝ $9.00Low
3/22/2022HC WainwrightLower TargetBuy$14.00 ➝ $11.00Low
10/14/2021B. RileyInitiated CoverageBuyHigh
9/7/2021HC WainwrightReiterated RatingBuy$14.00Low
8/16/2021B. RileyReiterated RatingBuyLow
8/9/2021HC WainwrightReiterated RatingBuy$14.00Low
6/29/2021HC WainwrightReiterated RatingBuy$14.00Low
6/1/2021B. RileyLower TargetBuy$13.00 ➝ $11.00Medium
3/17/2021HC WainwrightLower TargetBuy$15.00 ➝ $14.00Medium
1/4/2021HC WainwrightLower TargetBuy$20.00 ➝ $15.00N/A
9/30/2020HC WainwrightBoost TargetBuy$18.00 ➝ $20.00High
8/24/2020HC WainwrightReiterated RatingBuy$18.00High
5/26/2020HC WainwrightReiterated RatingBuy$26.00 ➝ $18.00High
5/15/2020B. RileyLower TargetBuy$12.00 ➝ $10.00Medium
3/30/2020HC WainwrightBoost TargetBuy$23.00 ➝ $26.00High
3/19/2020HC WainwrightReiterated RatingBuy$23.00Medium
1/28/2020HC WainwrightReiterated RatingBuy$21.00 ➝ $23.00High
12/30/2019HC WainwrightReiterated RatingBuy$21.00Medium
10/23/2019HC WainwrightReiterated RatingBuy$18.00 ➝ $21.00Low
9/20/2019B. RileyInitiated CoverageBuy$13.50High
8/5/2019Lake Street CapitalInitiated CoverageBuyLow
8/5/2019HC WainwrightReiterated RatingBuy$18.00High
(Data available from 6/24/2019 forward)

News Sentiment Rating

1.91 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/27/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 5 very negative mentions
3/26/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/25/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.
Eton Pharmaceuticals logo
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Read More

Today's Range

Now: $3.26
Low: $3.24
High: $3.35

50 Day Range

MA: $3.50
Low: $3.06
High: $3.75

52 Week Range

Now: $3.26
Low: $2.42
High: $5.81

Volume

3,985 shs

Average Volume

61,292 shs

Market Capitalization

$83.75 million

P/E Ratio

81.50

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Eton Pharmaceuticals?

The following sell-side analysts have issued reports on Eton Pharmaceuticals in the last twelve months: Craig Hallum, HC Wainwright, and TheStreet.
View the latest analyst ratings for ETON.

What is the current price target for Eton Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Eton Pharmaceuticals in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 169.5%. HC Wainwright has the highest price target set, predicting ETON will reach $10.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $8.00 for Eton Pharmaceuticals in the next year.
View the latest price targets for ETON.

What is the current consensus analyst rating for Eton Pharmaceuticals?

Eton Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ETON will outperform the market and that investors should add to their positions of Eton Pharmaceuticals.
View the latest ratings for ETON.

What other companies compete with Eton Pharmaceuticals?

How do I contact Eton Pharmaceuticals' investor relations team?

Eton Pharmaceuticals' physical mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company's listed phone number is (847) 787-7361 and its investor relations email address is [email protected]. The official website for Eton Pharmaceuticals is www.etonpharma.com. Learn More about contacing Eton Pharmaceuticals investor relations.